Biotech Takeover Targets Wall Street Eyes After Apogee Deal
AbbVie’s Apogee deal has revived takeover chatter. Three Nasdaq-listed biotech players are emerging as plausible biot...
Benchmarks provide objective yardsticks to assess results, set expectations, and keep portfolios aligned with objectives.
20,321 articlesAbbVie’s Apogee deal has revived takeover chatter. Three Nasdaq-listed biotech players are emerging as plausible biot...
Thailand confronts a high-stakes case that blends illegal crypto mining with money laundering. This article breaks do...
This article explores Baupost founder Seth Klarman's patient, risk-conscious investing style. Learn how his focus on ...
New-car payments are climbing fast, with 19% of buyers now paying $1,000 monthly. Delinquencies are rising and real w...
Could SpaceX stock reach $192 by 2027? This guide lays out the drivers, the math behind the target, and realistic ste...
As retirement checks begin, a rising share of households worry about debts that survive into retirement. The IRS can ...
Late-career workers who enroll in Medicare while still employed and continue HSA deposits risk a 6% annual excise tax...
A wave of billionaire fund managers are boosting Amazon bets as AI hype collides with a value play. Pershing Square, ...
European regulators press Binance on MiCA licensing as Greece withdraws its application and talks with Ireland and La...
Arm Holdings trades around $347 as investors weigh AI-driven demand and data-center opportunities. Analysts see a pat...
A high-profile congressman warns that Social Security could face cuts as the trust fund nears insolvency in the early...
Medicare Part B premiums and income-based IRMAA surcharges are reshaping retirement budgets in 2026. The typical reti...